371 completed, 84 recruiting, 70 terminated, 69 active not recruiting. 697 Phase 3, 86 Phase 2.
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Randomized, Multicenter, Non-inferiority Trial Comparing the Efficacy of Fosfomycin Versus Fluoroquinolones or Cotrimoxazole as Oral Follow-up Treatment in Febrile Urinary Tract Infections in Men Caused by Susceptible Enterobacteria Fosfomycin-trometamol, Reference treatments - Prostatitis, Escherichia Coli Infection | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 312 | 2026-12-01 | 2026-11-12 |
| Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule - Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | Il-Yang Pharm. Co., Ltd. | 660 | 2026-11-09 | 2026-10-13 |
| Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide - Prostatic Neoplasms, Biochemical Recurrence | Phase 3 | Not yet recruiting | Ente Ospedaliero Cantonale, Bellinzona | 140 | 2026-11-01 | 2026-08-24 |
| A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer JNJ-101556143, Placebo, Best Supportive Care - Prostatic Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 400 | 2026-10-29 | 2026-11-03 |
| ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) ZOLADEX 10.8 mg - High Risk Prostate Cancer | Phase 3 | Not yet recruiting | Dr. Tamim Niazi | 600 | 2026-10-01 | 2026-08-20 |
| Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer ultiparametric Magnetic Resonance Imaging, Perflutren lipid microsphere, Transrectal Ultrasound - Prostate Carcinoma | Phase 3 | Not yet recruiting | Thomas Jefferson University | 300 | 2026-10-01 | 2026-08-25 |
| Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup]) [68Ga]-LNTH-2401 - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Lantheus Medical Imaging | 408 | 2026-09-30 | 2026-09-21 |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) Saruparib, Placebo, Enzalutamide - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | AstraZeneca | 1330 | 2026-09-15 | 2026-10-15 |
| A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone - Neoplasms, Prostate | Phase 3 | Recruiting | GlaxoSmithKline | 684 | 2026-09-01 | 2026-10-02 |
| RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial Stereotactic body radiotherapy (SBRT) to the prostate bed, Standard-of-care radiotherapy (SOC) to the prostate bed - Prostate Cancer (Post Prostatectomy), Prostate Cancer | Phase 3 | Not yet recruiting | Robert Förster | 206 | 2026-09-01 | 2026-09-21 |
| Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer Experimental - BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 330 | 2026-09-01 | 2026-05-15 |
| Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) 177Lu-NYM032 injection, Best supportive/best standard of care - Prostate Cancer | Phase 3 | Not yet recruiting | Norroy Bioscience Co., LTD | 600 | 2026-08-31 | 2026-08-31 |
| This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. 68-Ga-NYM032 - Prostate Cancer | Phase 3 | Recruiting | Norroy Bioscience Co., LTD | 232 | 2026-08-31 | 2026-09-15 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-11-04 |
| Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. 68-Ga-NYM032 - Prostate Cancer (Diagnosis) | Phase 3 | Recruiting | Norroy Bioscience Co., LTD | 365 | 2026-08-06 | 2026-08-17 |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-11-03 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| FOsfomycin for Male Urinary Tract Infection Fosfomycun-trometamol - Urinary Tract Infection, Prostatitis | Phase 3 | Not yet recruiting | University Hospital, Rouen | 138 | 2026-07-01 | 2026-06-12 |
| QLC5508 in Participants With Metastatic Prostate Cancer QLC5508, Docetaxel - Prostate Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 700 | 2026-06-20 | 2026-06-08 |
Showing 20 of 697. Sign in to see all of them.
Prostatic Neoplasms (594) · Prostatic Hyperplasia (88) · Neoplasms (41) · Neoplasm Metastasis (28) · Breast Neoplasms (22) · Lower Urinary Tract Symptoms (13) · Pain (13) · Erectile Dysfunction (12) · Lung Neoplasms (12) · Prostatitis (11) · Prostatic Neoplasms, Castration-Resistant (10) · Osteoporosis (9) · Colorectal Neoplasms (8) · Ovarian Neoplasms (8) · Adenocarcinoma (7)
Genital Diseases (696) · Urogenital Diseases (696) · Male Urogenital Diseases (693) · Genital Diseases, Male (692) · Neoplasms by Site (597) · Genital Neoplasms, Male (595) · Urogenital Neoplasms (594) · Neoplasms (560) · Pathological Conditions, Signs and Symptoms (89) · Pathologic Processes (50) · Signs and Symptoms (44) · Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Neoplastic Processes (29)
Prednisone (65) · Docetaxel (63) · Radiotherapy (56) · Goserelin (52) · Leuprolide (52) · bicalutamide (48) · enzalutamide (42) · Androgen Antagonists (35) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (33) · Flutamide (26) · Triptorelin Pamoate (26) · Abiraterone Acetate (24) · abiraterone (22) · apalutamide (22) · Tamsulosin (19)
Ferring Pharmaceuticals (21) · Radiation Therapy Oncology Group (20) · Alliance for Clinical Trials in Oncology (17) · Sanofi (16) · AstraZeneca (14) · UNICANCER (13) · Eli Lilly and Company (12) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Novartis Pharmaceuticals (11) · Janssen Research & Development, LLC (10) · Pfizer (10) · Merck Sharp & Dohme LLC (9) · SWOG Cancer Research Network (9) · GlaxoSmithKline (8) · M.D. Anderson Cancer Center (8)
United States (334) · Canada (190) · France (143) · United Kingdom (127) · Germany (112) · Italy (104) · Netherlands (104) · Spain (102) · Belgium (98) · Australia (89) · Poland (89) · China (76) · South Korea (76) · Czechia (66) · Russia (62)
Michel Bolla, MD (5) · Silke Gillessen, Prof (5) · Thomas Hope, MD (5) · Eric J. Small, MD (4)
PMID 34350976, PMID 24722180, PMID 29272162, PMID 33270906, PMID 36884035, PMID 38320143, PMID 25592642, PMID 26299520, PMID 38421243, PMID 22129214, PMID 35643841, PMID 35731340, PMID 36596347, PMID 38421252, PMID 41698328, PMID 21135869, PMID 21917607, PMID 22747660, PMID 23228299, PMID 23234617, PMID 24423462, PMID 24957547, PMID 25712310, PMID 25829400, PMID 26031410, PMID 26278649, PMID 26609008, PMID 29500065, PMID 30920593, PMID 31830211, PMID 32808077, PMID 32878613, PMID 32994091, PMID 33740734, PMID 33999161, PMID 34518652, PMID 35812443, PMID 37121865, PMID 37751207, PMID 37951974, PMID 37973477, PMID 39163505, PMID 40539499, PMID 41880608, PMID 42286315, PMID 10604271, PMID 10717606, PMID 10866876, PMID 10869758, PMID 11289126
2023 (16), 2008 (10), 2018 (9), U10CA031946 (7), 2017 (6), 2009 (4), 2014 (4), 2016 (4), 2005 (3), 2015 (3), 2019 (3), 2025 (3), P30CA016672 (3), U10CA032102 (3), U10CA180820 (3)